Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trevor Kilpatrick

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Plos One|June 13, 2015
The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene FunctionJudith Field, Fernando Shahijanian, Stephen Schibeci, et al.
Multiple Sclerosis and Related Disorders|June 6, 2022
Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemicVivien Li, Izanne Roos, Mastura Monif, et al.
Trials|March 22, 2020
Correction to: Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trialLitza Kiropoulos, Trevor Kilpatrick, Tomas Kalincik, et al.
Trials|January 22, 2020
Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trialLitza Kiropoulos, Trevor Kilpatrick, Tomas Kalincik, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive testsDaniel Merlo, Tomas Kalincik, Chao Zhu, et al.
The Journal of Clinical Investigation|October 21, 2014
Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammationAnna Jonas, Stefan Thiem, Tanja Kuhlmann, et al.
Neurology|September 24, 2021
Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple SclerosisDaniel Merlo, Jim Stankovich, Claire Bai, et al.
Plos One|October 19, 2012
Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanismMelissa M Gresle, Estella Alexandrou, Qizhu Wu, et al.
Frontiers in Immunology|June 16, 2023
Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosisAlexandre Xavier, Maria Pia Campagna, Vicki E Maltby, et al.
Clinical Epigenetics|February 11, 2023
Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosisMaria Pia Campagna, Alexandre Xavier, Jim Stankovich, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Plos One|June 13, 2015
The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene FunctionJudith Field, Fernando Shahijanian, Stephen Schibeci, et al.
Multiple Sclerosis and Related Disorders|June 6, 2022
Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemicVivien Li, Izanne Roos, Mastura Monif, et al.
Trials|March 22, 2020
Correction to: Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trialLitza Kiropoulos, Trevor Kilpatrick, Tomas Kalincik, et al.
Trials|January 22, 2020
Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trialLitza Kiropoulos, Trevor Kilpatrick, Tomas Kalincik, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive testsDaniel Merlo, Tomas Kalincik, Chao Zhu, et al.
The Journal of Clinical Investigation|October 21, 2014
Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammationAnna Jonas, Stefan Thiem, Tanja Kuhlmann, et al.
Neurology|September 24, 2021
Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple SclerosisDaniel Merlo, Jim Stankovich, Claire Bai, et al.
Plos One|October 19, 2012
Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanismMelissa M Gresle, Estella Alexandrou, Qizhu Wu, et al.
Frontiers in Immunology|June 16, 2023
Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosisAlexandre Xavier, Maria Pia Campagna, Vicki E Maltby, et al.
Clinical Epigenetics|February 11, 2023
Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosisMaria Pia Campagna, Alexandre Xavier, Jim Stankovich, et al.
Pageof 5